Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-55308942 DDI study with CYP probes and oral contraceptives
NCT03547024Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanvipixant in bipolar disorder (BD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration, Area Under the Analyte Concentration-Time Curve from Time Zero to Last Measurable Concentration and 1 more. Started Jun 2018; status: completed.
02
Drugs
zanvipixant
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03547024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547024.